| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2′-Deoxy-2′-fluoroadenosine targets viral and cancer cell DNA replication. As a nucleoside analog, it is incorporated into DNA during replication, leading to chain termination or the induction of mutations that disrupt the replication process. Its mechanism of action involves interference with DNA synthesis, which is a common strategy for both antiviral and anticancer agents. It has been evaluated for its antiviral activity against influenza, SARS, HIV, and HCV.
|
|---|---|
| ln Vitro |
In vitro, 2′-Deoxy-2′-fluoroadenosine exhibits activity against a range of viruses and cancer cells. As a fluorinated deoxyadenosine, it can interfere with viral or cancer cell replication by being incorporated into DNA. It has been evaluated as an inhibitor of Hepacivirus C (HCV). Its activity is typically assessed in cell-based assays measuring the inhibition of viral replication or cancer cell proliferation. The compound's antitumor and antiviral properties make it a valuable tool for research.
|
| ln Vivo |
In vivo, 2′-Deoxy-2′-fluoroadenosine has been evaluated for its antiviral and antitumor potential. As a nucleoside analog, its in vivo efficacy would depend on its phosphorylation to the active triphosphate form and its incorporation into DNA. Studies in animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound is a fluorinated deoxyadenosine with antitumor and antiviral activity.
|
| Enzyme Assay |
For non-cellular enzyme/receptor binding studies, 2′-Deoxy-2′-fluoroadenosine's activity is evaluated in biochemical assays that measure its incorporation into DNA or its inhibition of DNA polymerases. As a nucleoside analog, it can be used in polymerase assays to study its ability to act as a chain terminator. Its antiviral activity can also be assessed in enzyme inhibition assays targeting viral polymerases, such as the HCV polymerase.
|
| Cell Assay |
For in vitro cellular experiments, cancer cell lines or virus-infected cells are cultured and treated with 2′-Deoxy-2′-fluoroadenosine at various concentrations. The compound's antiproliferative or antiviral effects are assessed using standard cell viability assays (e.g., MTT) to determine its IC50. For antiviral studies, the inhibition of viral replication is measured by quantifying viral RNA or protein levels. Its mechanism of action is confirmed by its ability to be incorporated into DNA.
|
| Animal Protocol |
For in vivo animal studies, xenograft mouse models bearing human tumors or animal models of viral infection are typically employed. 2′-Deoxy-2′-fluoroadenosine is administered via an appropriate route, such as intraperitoneal injection, at varying doses. Tumor volume is measured regularly, or viral load is assessed, to evaluate the compound's in vivo efficacy. Body weight is monitored to assess toxicity. The compound's mechanism of action is confirmed by its incorporation into DNA.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2′-Deoxy-2′-fluoroadenosine are not extensively detailed in the provided sources. It has a molecular weight of 269.24 and is soluble in DMSO at 50 mg/mL. It should be stored at 4°C, sealed. As a nucleoside analog, it is expected to be taken up by cells and phosphorylated to its active form. Comprehensive pharmacokinetic studies, including bioavailability, half-life, and tissue distribution, are needed to fully characterize its ADME properties.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 2′-Deoxy-2′-fluoroadenosine is not explicitly detailed in the provided sources. As a nucleoside analog, its safety is a key consideration. Standard laboratory safety precautions should be followed when handling this compound. While it has antitumor and antiviral activity, its potential for toxicity would be evaluated in preclinical studies. It is intended for research use only and is not for human therapeutic applications.
|
| References | |
| Additional Infomation |
2′-Deoxy-2′-fluoroadenosine is a fluorinated deoxyadenosine analog with a molecular formula of C10H12FN5O3 and a molecular weight of 269.24. It exhibits both antitumor and antiviral activity by being incorporated into DNA and interfering with replication. It has been evaluated as an inhibitor of HCV and other viruses. This research compound is for laboratory use only and has not been approved for clinical applications.
|
| Molecular Formula |
C10H12FN5O3
|
|---|---|
| Molecular Weight |
269.23
|
| Exact Mass |
269.092
|
| CAS # |
64183-27-3
|
| PubChem CID |
100253
|
| Appearance |
White to off-white solid powder
|
| Density |
2.0±0.1 g/cm3
|
| Boiling Point |
628.6±65.0 °C at 760 mmHg
|
| Flash Point |
334.0±34.3 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.834
|
| LogP |
-0.32
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)F)N
|
| InChi Key |
ZGYYPTJWJBEXBC-QYYRPYCUSA-N
|
| InChi Code |
InChI=1S/C10H12FN5O3/c11-5-7(18)4(1-17)19-10(5)16-3-15-6-8(12)13-2-14-9(6)16/h2-5,7,10,17-18H,1H2,(H2,12,13,14)/t4-,5-,7-,10-/m1/s1
|
| Chemical Name |
(2R,3R,4R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2-(hydroxymethyl)oxolan-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (185.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7143 mL | 18.5715 mL | 37.1430 mL | |
| 5 mM | 0.7429 mL | 3.7143 mL | 7.4286 mL | |
| 10 mM | 0.3714 mL | 1.8571 mL | 3.7143 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
